Flaig: It has been a remarkable 10 years for bladder cancer. If you think back to 10 or 15 years ago, we had no new ...
As new therapies emerge, particularly for non-muscle invasive disease, clinicians and patients are faced with increasingly ...
A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed ...
ImmunityBio heads into 2026 riding Anktiva growth, but upcoming bladder trial data and broader use in earlier care will be ...
In a phase 2 study, researchers added pembrolizumab to chemoradiation and surgery for muscle-invasive bladder cancer. 60 ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that ANKTIVA (R) (nogapendekin alfa inbakicept) is now commercially available in Saudi Arabia. Initial ...
Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...
Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...
A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which ...
While the method may sound unfamiliar, it has been clinically validated for decades and remains central to preventing ...
The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results